Avacta Group (AVCT.L)

Executive Summary

Avacta Group is a clinical-stage UK biopharmaceutical company developing tumor-activated therapies using its proprietary pre|CISION platform, which leverages a FAP-cleavable peptide to selectively release potent drug payloads within the tumor microenvironment. This approach aims to enhance efficacy while minimizing systemic toxicity. The company's lead candidate, AVA6000, is in Phase 1 trials for multiple solid tumors (salivary gland, urothelial carcinoma, ovarian carcinoma, breast cancer, soft tissue sarcoma) with estimated completion in August 2026. Additionally, Avacta initiated a Phase 1 trial for AVA6103 in March 2026 targeting various adenocarcinomas. With a market cap of ~£366M and a novel platform, Avacta represents an early-stage opportunity in immuno-oncology, with potential value inflection from upcoming clinical data.

Upcoming Catalysts (preview)

• Q3 2026AVA6000 Phase 1 Dose-Escalation Data60% success
• H1 2027AVA6103 Initial Safety and Tolerability Readout50% success